4D Molecular Therapeutics Inc Ordinary Shares FDMT
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if FDMT is a good fit for your portfolio.
News
-
4DMT Announces Update on Regulatory Interactions and Development Path for 4D-710 for Treatment of Cystic Fibrosis
-
4DMT to Participate in Upcoming Investor Conferences
-
4DMT Reports Full Year 2023 Financial Results and Operational Highlights
-
4DMT Presents Interim Data from 4D-310 INGLAXA Phase 1/2 Clinical Trials for Fabry Disease Cardiomyopathy at WORLDSymposium™ 2024
-
4D Molecular Therapeutics Announces Pricing of Upsized Public Offering of Common Stock
-
Thinking about trading options or stock in C3.ai, Meta Platforms, 4D Molecular Therapeutics, Li Auto, or Varonis Systems?
-
4D Molecular Therapeutics Announces Proposed Public Offering of Common Stock
-
Thinking about buying stock in Chenghe Acquisition, Vertex Pharmaceuticals, VinFast Auto, 4D Molecular Therapeutics, or MicroCloud Hologram?
Trading Information
- Previous Close Price
- $23.53
- Day Range
- $22.75–23.86
- 52-Week Range
- $9.44–36.25
- Bid/Ask
- $21.14 / $24.40
- Market Cap
- $1.19 Bil
- Volume/Avg
- 322,784 / 1.2 Mil
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 44.43
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
4D Molecular Therapeutics Inc is a clinical-stage gene therapy company engaged in the development of product candidates using targeted and evolved AAV vectors. It has built a portfolio of gene therapy product candidates focused on three therapeutic areas: Ophthalmology (intravitreal vector) includes 4D-150, 4D-125, 4D-110, and 4D-175; Cardiology (intravenous vector) includes 4D-710, 4D-725, and Pulmonology (aerosol vector) 4D-310.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Core
- Total Number of Employees
- 147
Comparables
Valuation
|
Metric
|
FDMT
|
SWTX
|
KPTI
|
|---|---|---|---|
Price/Earnings (Normalized) | — | — | — |
Price/Book Value | 3.29 | 5.19 | — |
Price/Sales | 44.43 | 512.22 | 0.83 |
Price/Cash Flow | — | — | — |
Price/Earnings
FDMT
SWTX
KPTI
Financial Strength
|
Metric
|
FDMT
|
SWTX
|
KPTI
|
|---|---|---|---|
Quick Ratio | 15.21 | 6.21 | 3.14 |
Current Ratio | 15.65 | 6.41 | 3.37 |
Interest Coverage | — | — | −5.45 |
Quick Ratio
FDMT
SWTX
KPTI
Profitability
|
Metric
|
FDMT
|
SWTX
|
KPTI
|
|---|---|---|---|
Return on Assets (Normalized) | −25.94% | −39.61% | −42.20% |
Return on Equity (Normalized) | −28.64% | −45.43% | — |
Return on Invested Capital (Normalized) | −31.25% | −49.28% | −111.18% |
Return on Assets
FDMT
SWTX
KPTI
Biotechnology Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|
NVO
| Novo Nordisk A/S ADR | Jxwnzjbzd | Rdhq | $554.7 Bil | |
VRTX
| Vertex Pharmaceuticals Inc | Bpzdkyc | Pghbnck | $102.7 Bil | |
REGN
| Regeneron Pharmaceuticals Inc | Cpbdqdc | Mmrmlh | $97.8 Bil | |
MRNA
| Moderna Inc | Rydxbhqm | Ztls | $41.3 Bil | |
ARGX
| argenx SE ADR | Kbprwlsv | Jch | $22.3 Bil | |
BNTX
| BioNTech SE ADR | Shlgcnkkk | Jmbk | $21.0 Bil | |
ALNY
| Alnylam Pharmaceuticals Inc | Tbnrcydlt | Vvgfbr | $18.2 Bil | |
BMRN
| Biomarin Pharmaceutical Inc | Rrpdcqyz | Npgdd | $15.4 Bil | |
RPRX
| Royalty Pharma PLC Class A | Mrfdkrswm | Dmyrjrm | $12.5 Bil | |
INCY
| Incyte Corp | Xljmngkl | Pvkzg | $11.6 Bil |